Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H17N3O3 |
Molecular Weight | 239.271 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C(C=NN(C)C1=O)N2CCOCC2
InChI
InChIKey=URJQOOISAKEBKW-UHFFFAOYSA-N
InChI=1S/C11H17N3O3/c1-3-17-10-9(8-12-13(2)11(10)15)14-4-6-16-7-5-14/h8H,3-7H2,1-2H3
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/1545477Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/7201806, http://www.ncbi.nlm.nih.gov/pubmed/6172134
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1545477
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/7201806, http://www.ncbi.nlm.nih.gov/pubmed/6172134
Emorfazone is an analgetic agent that was developed by Morishita Pharmaceutical in Japan. The drug was tested for its ability to treat dental pain and inflammation in double blind study and was shown to be effective, however the exact mechanism of its action still remains unknown. Moreover, it is supposed that the effect is not mediated by interaction with opioids receptors or with prostaglandins synthesis.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/575516
Curator's Comment: The effect on CNS was tested in rats and mice.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1545477
Emorfazone 400 mg thrice daily for two days followed by emorfazone 200 mg thrice daily for the next four days.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID0022981
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
4942
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
C018432
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
C73085
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103954
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
38957-41-4
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
100000080201
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
m4889
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB06511MIG
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
V93U9DH62C
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
254-220-9
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
1002
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY | |||
|
3221
Created by
admin on Fri Dec 15 16:37:04 GMT 2023 , Edited by admin on Fri Dec 15 16:37:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY